ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016
SATB2 suppresses gastric cancer cell proliferation and migration.
Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 25 citations in OpenAlex.
- Bone and Extracellular Signal-Related Kinase 5 (ERK5).Biomolecules · 2024Review
- SATB2 drives glioblastoma growth by recruiting CBP to promote FOXM1 expression in glioma stem cells.EMBO molecular medicine · 2020Article
- MAP Kinases Pathways in Gastric Cancer.International journal of molecular sciences · 2020Review
- Impact of ERK5 on the Hallmarks of Cancer.International journal of molecular sciences · 2019Review
- Role of miR-31 and SATB2 in arsenic-induced malignant BEAS-2B cell transformation.Molecular carcinogenesis · 2018Article
- SATB2 suppresses non-small cell lung cancer invasiveness by G9a.Clinical and experimental medicine · 2018Article
- Oncogenic and tumor suppressive roles of special AT-rich sequence-binding protein.Journal of carcinogenesis · 2018Review
- SATB2-associated syndrome: Mechanisms, phenotype, and practical recommendations.American journal of medical genetics. Part A · 2017Review
- SATB2 induces stem-like properties and promotes epithelial-mesenchymal transition in hepatocellular carcinoma.International journal of clinical and experimental pathology · 2017Article
- Molecular Mechanisms of Malignant Transformation by Low Dose Cadmium in Normal Human Bronchial Epithelial Cells.PloS one · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer is one of the death-related malignant tumors worldwide. It remains a challenge for the diagnosis and treatment of gastric cancer. Special AT-rich sequence-binding protein 2 (SATB2) is a new tumor suppressive gene and plays important roles in many cancers. However, the role of SATB2 in gastric cancer is still unknown. In the present study, we demonstrated that downregulation of SATB2 was associated with shortened survival in patients with gastric cancer. Ectopic expression of SATB2 inhibited gastric cancer cell proliferation, colony formation, and migration. Overexpression of SATB2 repressed the expression of extracellular signal-regulated kinase 5 (ERK5), and activation of ERK5 restored the SATB2-induced inhibition of proliferation and migration in gastric cancer. This study provided evidence that SATB2 acted as a tumor suppressive gene gastric cancer, serving as a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.